AI Generated Image
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
The New York Times • • business
Key Points:
- An FDA advisory panel recommended expanding the use of six unproven peptides through compounding pharmacies, raising concerns about the safety and regulation of these substances.
- The recommendation allows specialized pharmacies to produce these peptides for patients, a practice originally intended for exceptional cases but now growing into a larger business.
- FDA scientists expressed alarm over the panel's decisions, highlighting that the peptides lack thorough FDA approval and may pose health risks that are difficult to monitor.
- The panel's decisions align with the Trump administration's increasing openness to wellness products popularized by influencers, despite safety concerns.
- While six peptides were endorsed, the panel rejected broader use of one rarely used peptide, reflecting some caution amidst the broader approvals.
